Navigation Links
Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain
Date:6/1/2009

Some reduction in mortality rates found, but experts say more follow-up needed

MONDAY, June 1 (HealthDay News) -- Patients checked for colon cancer with a procedure called flexible sigmoidoscopy showed no significant reduction in risk over seven years, but the screening did seem to lower the risk of dying from the disease, Norwegian researchers report.

There are several methods available for colon cancer screening including colonoscopy, which involves a look at the whole colon and the removal of any precancerous or cancerous polyps. In addition, there is flexible sigmoidoscopy, which uses a flexible endoscope to examine the large intestine only. There are also noninvasive tests such as fecal occult blood sampling and CT colonoscopy.

"Flexible sigmoidoscopy screening looks promising, but the effect on a population level appears less than expected and further follow-up is required," said lead researcher Dr. Geir Hoff, from the Cancer Registry of Norway in Oslo.

These are the first results from the trial, and it may be that seven years is too short a time to see the true effect of screening, Hoff said.

"The results suggest that flexible sigmoidoscopy screening may be a very efficient way of screening with an aim of reducing mortality and the risk of getting colorectal cancer, but the effect may be less than anticipated and certainly occurs later than expected in the follow-up period," Hoff added.

Until now, there have been results from randomized trials only for one colorectal cancer screening modality -- screening for blood in the stools, Hoff said. "Still, colonoscopy is recommended in several European countries and the U.S.," he added.

The report is published in the June 1 online edition of the BMJ, to coincide with the scheduled presentation of the findings Monday at the Digestive Diseases Week meeting in Chicago.

For the study, Hoff's team randomly assigned almost 56,000 men and women, aged 55 to 64, to be invited to screening for colon cancer with flexible sigmoidoscopy, while the others were not invited. The researchers followed all the participants for an average of seven years.

Hoff's group found no significant difference between the two groups in the number of those who developed colon cancer. Among those in the group that was invited to get screened, death from colon cancer was reduced by 27 percent compared with those who were not screened, but that percentage was not statistically significant, the researchers noted.

However, for those who actually underwent screening, death from colon cancer was reduced by 59 percent compared with people in the non-screening group. Moreover, for cancers that could have been found by flexible sigmoidoscopy, death from colon cancer was reduced by 76 percent, the team noted.

Both reductions in mortality are significant, the researchers say. But according to Hoff, the drop in deaths might also be due to what researchers call "self-selection bias": Heath-conscious people may be the ones choosing to get screened.

"A major reason for non-compliance to screening is that people are not convinced that there is 'anything in it for them,'" Hoff said. "Being able to quantify an effect to present potential screening participants requires randomized trials like this one. The study illustrates the need for randomized population screening trials before recommending widespread use of screening."

Dr. Thomas Imperiale, a professor of medicine at Indiana University Medical Center in Indianapolis and author of an accompanying journal editorial, noted that seven years was still too short a time to see a reduction in colon cancer from screening. And he advises everyone that it's better to get screened than not.

"These are early results. They show some promising findings," Imperiale said, but "we would not yet expect to see a reduction in colorectal cancer."

"There are options, which is good," Imperiale said. "The bottom line is that people should do something. What they do depends on their preferences and their risk, but they should do something -- do a test."

Another expert, Dr. Durado Brooks, director of colon and prostate cancer prevention programs at the American Cancer Society, agreed that seven years may be too short a follow-up.

In the study, there was a trend toward fewer incidence of cancer after screening, Brooks, said. "One of the questions is, is seven years too short a window? If they look at this again in another four or five years will the difference be statistically significant?"

Brooks noted that some countries have started mass colon cancer screening programs using flexible sigmoidoscopy, "because it is lot more available and less expensive than trying to screen everyone with colonoscopy. Flexible sigmoidoscopy is one of the methods recommended for screening by all of the major organizations."

More information

For more information on colon cancer, visit the American Cancer Society.



SOURCES: Geir Hoff, M.D., Ph.D., The Cancer Registry of Norway, Oslo; Thomas Imperiale, M.D., professor, medicine, Indiana University Medical Center, Indianapolis; Durado Brooks, M.D., director, colon and prostate cancer prevention programs, American Cancer Society, Atlanta; June 1, 2009, BMJ, online; June 1, 2009, presentation, Digestive Diseases Week, Chicago


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Not Worthy of Support? Democratic Leaders Continue to Ignore Americas Youth
2. Pricey Running Shoes Not Worth It: Study
3. Knights to Distribute $1 Million Worth of Wheelchairs for Veterans
4. Knights Distribute $1 Million Worth of Wheelchairs to Veterans
5. Jury Awards $5.25 Million Malpractice Verdict Against Fort Worth Doctor
6. Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas
7. Taxol with avastin produces noteworthy results
8. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
9. A Fort Worth Couple Sues Huguley Memorial Medical Center
10. Renaissance Health Publishing, LLC Warns the Public that ConsumerLab.com is Not Independent and Labels the CL Seal of Approval a Worthless, Paid-For Advertising Gimmick
11. Social Security Is Worth $225,000 for a Typical Retiree
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination ... are complicated and require expert user knowledge. In a live webinar on April ... the simplified, yet highly accurate, determination of sodium. , It has long been ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center ... Monday, April 3rd to commemorate the two-year anniversary of the facility. The event ... celebrate two great years while also familiarizing themselves with the facility. , In ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Harris Communications, Inc., ... hearing, is bringing its latest products to the Deaf Seniors of America Conference, April ... the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and to ...
(Date:3/25/2017)... Wisconsin (PRWEB) , ... March 25, 2017 , ... Norland at Swissray is ... composition analyzers for large subjects. The ELITE DXA has an active scan window, which ... wide or long to fit in the scan area could not undergo an accurate total ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... will spark a conversation on the current obstacles facing infection prevention and offer ... preventable deaths caused by these infections. , The print component of “Fighting ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... FRANCISCO , March 27, 2017  Twist Bioscience, ... DNA synthesis, today announced that it raised an additional ... total of $166 million. "It is ... we expand our reach and continue to deliver industry-leading ... multiple market segments," commented Emily M. Leproust, Ph.D., CEO ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. (NASDAQ: ... life-threatening inherited liver diseases in children, today reported ... year ended December 31, 2016 and provided an ... "PhaseRx continued to make progress during the fourth ... results from our non-human primate safety study, and with ...
(Date:3/27/2017)... 2017 Invivotek, LLC, a Genesis Biotechnology Group ... pharmacology contract research organization (CRO), announced the completion ... expanded preclinical research facility in Hamilton, New ... renewable energy source to reduce costs and lessen the ... Genesis Solar Farm follows Invivotek,s recent expansion from a ...
Breaking Medicine Technology: